Literature DB >> 9757011

Alzheimer's beta-amyloid peptides induce inflammatory cascade in human vascular cells: the roles of cytokines and CD40.

Z Suo1, J Tan, A Placzek, F Crawford, C Fang, M Mullan.   

Abstract

Accumulating evidence suggests that beta-amyloid (Abeta)-induced inflammatory reactions may partially drive the pathogenesis of Alzheimer's disease (AD). Recent data also implicate similar inflammatory processes in cerebral amyloid angiopathy (CAA). To evaluate the roles of Abeta in the inflammatory processes in vascular tissues, we have tested the ability of Abeta to trigger inflammatory responses in cultured human vascular cells. We found that stimulation with Abeta dose-dependently increased the expression of CD40, and secretion of interferon-gamma (IFN-gamma) and interleukin-1beta (IL-1beta) in endothelial cells. Abeta also induced expression of IFN-gamma receptor (IFN-gammaR) both in endothelial and smooth muscle cells. Characterization of the Abeta-induced inflammatory responses in the vascular cells showed that the ligation of CD40 further increased cytokine production and/or the expression of IFN-gammaR. Moreover, IL-1beta and IFN-gamma synergistically increased the Abeta-induced expression of CD40 and IFN-gammaR. We have recently found that Abeta induces expression of adhesion molecules, and that cytokine production and interaction of CD40-CD40 ligand (CD40L) further increase the Abeta-induced expression of adhesion molecules in these same cells. These results suggest that Abeta can function as an inflammatory stimulator to activate vascular cells and induces an auto-amplified inflammatory molecular cascade, through interactions among adhesion molecules, CD40-CD40L and cytokines. Additionally, Abeta1-42, the more pathologic form of Abeta, induces much stronger effects in endothelial cells than in smooth muscle cells, while the reverse is true for Abeta1-40. Collectively, these findings support the hypothesis that the Abeta-induced inflammatory responses in vascular cells may play a significant role in the pathogenesis of CAA and AD. Copyright 1998 Elsevier Science B.V.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9757011     DOI: 10.1016/s0006-8993(98)00780-x

Source DB:  PubMed          Journal:  Brain Res        ISSN: 0006-8993            Impact factor:   3.252


  36 in total

1.  Peripherally administered human umbilical cord blood cells reduce parenchymal and vascular beta-amyloid deposits in Alzheimer mice.

Authors:  William V Nikolic; Huayan Hou; Terrence Town; Yuyan Zhu; Brian Giunta; Cyndy D Sanberg; Jin Zeng; Deyan Luo; Jared Ehrhart; Takashi Mori; Paul R Sanberg; Jun Tan
Journal:  Stem Cells Dev       Date:  2008-06       Impact factor: 3.272

Review 2.  Impact of the CD40-CD40L dyad in Alzheimer's disease.

Authors:  Brian Giunta; Kavon Rezai-Zadeh; Jun Tan
Journal:  CNS Neurol Disord Drug Targets       Date:  2010-04       Impact factor: 4.388

Review 3.  Neuroinflammation in Alzheimer's disease: chemokines produced by astrocytes and chemokine receptors.

Authors:  Chang Liu; Guohong Cui; Meiping Zhu; Xiangping Kang; Haidong Guo
Journal:  Int J Clin Exp Pathol       Date:  2014-12-01

4.  EVALUATION OF HOW CIGARETTE SMOKE IS A DIRECT RISK FACTOR FOR ALZHEIMER'S DISEASE.

Authors:  Brian Giunta; Juan Deng; Jingji Jin; Edin Sadic; Saja Rum; Huadong Zhou; Paul Sanberg; Jun Tan
Journal:  Technol Innov       Date:  2012-01-01

5.  Multiple low-dose infusions of human umbilical cord blood cells improve cognitive impairments and reduce amyloid-β-associated neuropathology in Alzheimer mice.

Authors:  Donna Darlington; Juan Deng; Brian Giunta; Huayan Hou; Cyndy D Sanberg; Nicole Kuzmin-Nichols; Hua-Dong Zhou; Takashi Mori; Jared Ehrhart; Paul R Sanberg; Jun Tan
Journal:  Stem Cells Dev       Date:  2012-09-05       Impact factor: 3.272

Review 6.  Inflammation and Alzheimer's disease.

Authors:  H Akiyama; S Barger; S Barnum; B Bradt; J Bauer; G M Cole; N R Cooper; P Eikelenboom; M Emmerling; B L Fiebich; C E Finch; S Frautschy; W S Griffin; H Hampel; M Hull; G Landreth; L Lue; R Mrak; I R Mackenzie; P L McGeer; M K O'Banion; J Pachter; G Pasinetti; C Plata-Salaman; J Rogers; R Rydel; Y Shen; W Streit; R Strohmeyer; I Tooyoma; F L Van Muiswinkel; R Veerhuis; D Walker; S Webster; B Wegrzyniak; G Wenk; T Wyss-Coray
Journal:  Neurobiol Aging       Date:  2000 May-Jun       Impact factor: 4.673

7.  Reducing cerebral microvascular amyloid-beta protein deposition diminishes regional neuroinflammation in vasculotropic mutant amyloid precursor protein transgenic mice.

Authors:  Jianting Miao; Michael P Vitek; Feng Xu; Mary Lou Previti; Judianne Davis; William E Van Nostrand
Journal:  J Neurosci       Date:  2005-07-06       Impact factor: 6.167

8.  A Novel Apolipoprotein E Antagonist Functionally Blocks Apolipoprotein E Interaction With N-terminal Amyloid Precursor Protein, Reduces β-Amyloid-Associated Pathology, and Improves Cognition.

Authors:  Darrell Sawmiller; Ahsan Habib; Huayan Hou; Takashi Mori; Anran Fan; Jun Tian; Jin Zeng; Brian Giunta; Paul R Sanberg; Mark P Mattson; Jun Tan
Journal:  Biol Psychiatry       Date:  2019-05-02       Impact factor: 13.382

9.  SOLUBLE CD40 LIGAND IN DEMENTIA.

Authors:  B Giunta; K P Figueroa; T Town; J Tan
Journal:  Drugs Future       Date:  2009-04-01       Impact factor: 0.148

10.  Flavonoid-mediated presenilin-1 phosphorylation reduces Alzheimer's disease beta-amyloid production.

Authors:  Kavon Rezai-Zadeh; R Douglas Shytle; Yun Bai; Jun Tian; Huayan Hou; Takashi Mori; Jin Zeng; Demian Obregon; Terrence Town; Jun Tan
Journal:  J Cell Mol Med       Date:  2008-04-09       Impact factor: 5.310

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.